What is DoseMe?
DoseMe operates at the intersection of pharmacology and digital health, providing a sophisticated platform known as DoseMeRx. The company specializes in model-informed precision dosing, a methodology that shifts clinical practice away from one-size-fits-all population averages toward highly individualized therapeutic regimens. By integrating complex pharmacokinetic and pharmacodynamic modeling with real-time patient data—such as laboratory results and specific physiological markers—the software enables clinicians to optimize medication safety and efficacy. This evidence-based approach is designed to mitigate the risks associated with traditional dosing, thereby enhancing patient outcomes within high-acuity hospital environments and pharmacy settings.
The platform serves as a vital tool for healthcare providers who require precision in managing narrow therapeutic index drugs. By automating the calculation of personalized doses, DoseMe reduces the cognitive burden on medical staff while simultaneously improving the accuracy of treatment plans. This technological integration represents a fundamental shift in how hospitals manage complex drug therapies, positioning the company as an essential partner for institutions prioritizing patient safety and clinical excellence.
How much funding has DoseMe raised?
DoseMe has raised a total of $3.1M across 2 funding rounds:
Angel/Seed
$500K
Series A
$2.6M
Angel/Seed (2014): $500K, investors not publicly disclosed
Series A (2016): $2.6M, investors not publicly disclosed
Key Investors in DoseMe
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for DoseMe?
With the recent infusion of capital, DoseMe is well-positioned to accelerate its enterprise-level expansion and deepen its integration within global healthcare systems. The strategic focus will likely center on scaling the DoseMeRx platform to support a broader range of therapeutic areas and expanding its footprint in major clinical networks. As the demand for precision medicine continues to rise, the company is expected to prioritize further research and development in predictive modeling, ensuring that its software remains at the forefront of clinical innovation. Future growth will be defined by the firm's ability to translate complex pharmacological data into actionable, bedside insights for clinicians worldwide.
See full DoseMe company page
